Two or more of the following factors conferred higher risk for virologic failure: Preexisting rilpivirine resistance mutations, HIV subtype A6/A1, or obesity.
Long-acting injectable cabotegravir + rilpivirine is approved for treatment of HIV in people who are virologically suppressed on an antiretroviral regimen and who do not have a history of treatment failure or resistance to either medication. Now, a post hoc analysis of participants in the registrational randomized trials reveals risk factors for virologic failure with this combination.
Among some 1600 participants in the ATLAS, ATLAS-2M, and FLAIR trials, 1.4% developed confirmed virologic failure (CVF). Most participants who developed CVF did so early (median, 25 weeks). Risk factors for CVF included presence of rilpivirine resistance mutations (detected post hoc on proviral genotyping); HIV subtype A6/A1 (more common in Eastern Europe, Rus…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)